Edwards Lifesciences Q2 FY26 EPS drops to $0.42; net sales rise 13.6% to $1.74 billion

Reuters2026/07/23 20:37

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Edwards Lifesciences Q2 net sales rose 13.6% to USD 1.74 billion; GAAP diluted EPS fell to USD 0.42.
GAAP net income attributable to shareholders dropped to USD 241.9 million; effective tax rate widened to 53.6%.
TMTT net sales more than doubled to USD 195.9 million; TAVR net sales climbed 11.3% to USD 1.26 billion.
2026 outlook raised for total company net sales growth to 10%-11%; adjusted EPS guidance held at USD 2.95-3.05.
CEO Bernard Zovighian cited stronger-than-expected sales growth, supported by contributions across regions and therapies including TAVR, mitral, tricuspid, surgical.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607231615BIZWIRE_USPR_____20260723_BW783980) on July 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Edwards Lifesciences Q2 FY26 EPS drops to $0.42; net sales rise 13.6% to $1.74 billion

You may also like

Crypto prices